Integrated Analysis and Network Pharmacology Approaches to Explore Key Genes of Xingnaojing for Treatment of Alzheimer's Disease

Overview

Journal Brain Behav

Specialty Psychology

Date 2020 Apr 19

PMID 32304290

Citations 8

Authors

Meixia Wang

Shouyong Wang

Yong Li

Gaomei Cai

Min Cao

Lanfang Li

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD), as a neurodegenerative condition, is one of the leading causes of dementia. Our study aims to explore the key genes of Xingnaojing (XNJ) for treatment of AD by integrated microarray analysis and network pharmacology.

Methods: The differentially expressed genes (DEGs) were identified in AD compared with normal control. According to these DEGs, we performed the functional annotation, protein-protein interaction (PPI) network construction. The network pharmacology was used to explore the potential targets of XNJ in the treatment of AD. The expression level of selected candidate genes was validated by quantitative real-time polymerase chain reaction (qRT-PCR).

Results: A total of 1,424 DEGs (620 genes were upregulated and 804 genes were downregulated) between AD and normal control were obtained. The functional annotation results displayed that neuroactive ligand-receptor interaction, regulation of actin cytoskeleton, Estrogen signaling pathway and notch signaling pathway were significantly enriched pathways in AD. Comparing the target genes of four active ingredients, a total of 16 shared genes were found. Among which, HTR2A and ADRA2A were also enriched in pathway of neuroactive ligand-receptor interaction. The expression of 4 DEGs (SORCS3, HTR2A, NEFL, and TAC1) was validated by qRT-PCR. Except for TAC1, the other 3 DEGs in AD were consistent with our integrated analysis.

Conclusions: The results of this study may provide novel insights into the molecular mechanisms of AD and indicate potential therapeutic targets for AD.

Citing Articles

Estrogen Receptors: A New Frontier in Alzheimer's Disease Therapy.

Cipriano G, Mazzon E, Anchesi I Int J Mol Sci. 2024; 25(16).

PMID: 39201762 PMC: 11354998. DOI: 10.3390/ijms25169077.

Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer's disease.

Salasova A, Monti G, Andersen O, Nykjaer A Mol Neurodegener. 2022; 17(1):74.

PMID: 36397124 PMC: 9673319. DOI: 10.1186/s13024-022-00576-2.

Alzheimer-Compound Identification Based on Data Fusion and forgeNet_SVM.

Yang B, Bao W, Hong S Front Aging Neurosci. 2022; 14:931729.

PMID: 35959292 PMC: 9357977. DOI: 10.3389/fnagi.2022.931729.

Genome-wide association study of brain arteriolosclerosis.

Shade L, Katsumata Y, Hohman T, Nho K, Saykin A, Mukherjee S J Cereb Blood Flow Metab. 2022; 42(8):1437-1450.

PMID: 35156446 PMC: 9274864. DOI: 10.1177/0271678X211066299.

Transcriptional Pathology Evolves over Time in Rat Hippocampus after Lateral Fluid Percussion Traumatic Brain Injury.

Catta-Preta R, Zdilar I, Jenner B, Doisy E, Tercovich K, Nord A Neurotrauma Rep. 2021; 2(1):512-525.

PMID: 34909768 PMC: 8667199. DOI: 10.1089/neur.2021.0021.

References

Reitz C . The role of intracellular trafficking and the VPS10d receptors in Alzheimer's disease. Future Neurol. 2012; 7(4):423-431. PMC: 3524993. DOI: 10.2217/fnl.12.31. View

Weston P, Poole T, Ryan N, Nair A, Liang Y, Macpherson K . Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017; 89(21):2167-2175. PMC: 5696646. DOI: 10.1212/WNL.0000000000004667. View

Zetterberg H, Hietala M, Jonsson M, Andreasen N, Styrud E, Karlsson I . Neurochemical aftermath of amateur boxing. Arch Neurol. 2006; 63(9):1277-80. DOI: 10.1001/archneur.63.9.1277. View

Jarrell J, Gao L, Cohen D, Huang X . Network Medicine for Alzheimer's Disease and Traditional Chinese Medicine. Molecules. 2018; 23(5). PMC: 6099497. DOI: 10.3390/molecules23051143. View

Quan X, Liang H, Chen Y, Qin Q, Wei Y, Liang Z . Related Network and Differential Expression Analyses Identify Nuclear Genes and Pathways in the Hippocampus of Alzheimer Disease. Med Sci Monit. 2020; 26:e919311. PMC: 7001513. DOI: 10.12659/MSM.919311. View

Lin J, Jiang M, Kan Z, Chu Y . Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014; 168:430-8. DOI: 10.1016/j.jad.2014.06.012. View

Ni H, Xu M, Zhan G, Fan Y, Zhou H, Jiang H . The GWAS Risk Genes for Depression May Be Actively Involved in Alzheimer's Disease. J Alzheimers Dis. 2018; 64(4):1149-1161. DOI: 10.3233/JAD-180276. View

Gotovac K, Nikolac Perkovic M, Pivac N, Borovecki F . Biomarkers of aggression in dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 69:125-30. DOI: 10.1016/j.pnpbp.2016.03.002. View

Ramanathan S, Glatt S . Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009; 17(10):839-46. DOI: 10.1097/JGP.0b013e3181ab8c3f. View

10.

Hermey G, Hoffmeister-Ullerich S, Merz B, Gross D, Kuhl D, Kins S . Amyloidosis causes downregulation of SorLA, SorCS1 and SorCS3 expression in mice. Biol Chem. 2019; 400(9):1181-1189. DOI: 10.1515/hsz-2019-0146. View

11.

Perlman L, Gottlieb A, Atias N, Ruppin E, Sharan R . Combining drug and gene similarity measures for drug-target elucidation. J Comput Biol. 2011; 18(2):133-45. DOI: 10.1089/cmb.2010.0213. View

12.

Feher A, Juhasz A, Laszlo A, Pakaski M, Kalman J, Janka Z . Serotonin transporter and serotonin receptor 2A gene polymorphisms in Alzheimer's disease. Neurosci Lett. 2013; 534:233-6. DOI: 10.1016/j.neulet.2012.12.020. View

13.

Fabbri C, Marsano A, Serretti A . Genetics of serotonin receptors and depression: state of the art. Curr Drug Targets. 2013; 14(5):531-48. DOI: 10.2174/1389450111314050004. View

14.

Yao F, Zhang K, Zhang Y, Guo Y, Li A, Xiao S . Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation. Front Neurol. 2019; 9:1158. PMC: 6331438. DOI: 10.3389/fneur.2018.01158. View

15.

Reitz C, Tokuhiro S, Clark L, Conrad C, Vonsattel J, Hazrati L . SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol. 2011; 69(1):47-64. PMC: 3086759. DOI: 10.1002/ana.22308. View

16.

Reitz C, Tosto G, Vardarajan B, Rogaeva E, Ghani M, Rogers R . Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP). Transl Psychiatry. 2013; 3:e256. PMC: 3669917. DOI: 10.1038/tp.2013.13. View

17.

Preische O, Schultz S, Apel A, Kuhle J, Kaeser S, Barro C . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2):277-283. PMC: 6367005. DOI: 10.1038/s41591-018-0304-3. View

18.

Reitz C . The role of the retromer complex in aging-related neurodegeneration: a molecular and genomic review. Mol Genet Genomics. 2014; 290(2):413-27. PMC: 4363161. DOI: 10.1007/s00438-014-0939-9. View

19.

Wang Y, Wu N, Liu J, Wu Z, Dong D . FusionCancer: a database of cancer fusion genes derived from RNA-seq data. Diagn Pathol. 2015; 10:131. PMC: 4517624. DOI: 10.1186/s13000-015-0310-4. View

20.

Isaev N, Stelmashook E, Genrikhs E, Oborina M, Kapkaeva M, Skulachev V . Alzheimer's Disease: An Exacerbation of Senile Phenoptosis. Biochemistry (Mosc). 2015; 80(12):1578-81. DOI: 10.1134/S0006297915120056. View